Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes

Heart

Volumn 98, Issue 10, 2012, Pages 786-791

  Røysland, Ragnhild ^a,b   Bonaca, Marc P ^c   Omland, Torbjørn ^a,b   Sabatine, Marc ^c   Murphy, Sabina A ^c   Scirica, Benjamin M ^c   Bjerre, Mette ^d,e   Flyvbjerg, Allan ^d,e   Braunwald, Eugene ^c   Morrow, David A ^c  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPROTEGERIN; PLACEBO; RANOLAZINE;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; AGED; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON ST ELEVATION ACUTE CORONARY SYNDROME; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY;

ACETANILIDES; ACUTE CORONARY SYNDROME; AGED; BIOLOGICAL MARKERS; CAUSE OF DEATH; ELECTROCARDIOGRAPHY; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NORWAY; OSTEOPROTEGERIN; PIPERAZINES; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84860919283     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2011-301260     Document Type: Article

References (30)

1. Abedin M, Omland T, Ueland T, et al. Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol 2007;99:513-18. (Pubitemid 46215559)
2. Van CA, Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 2009;204:321-9.
3. Ovchinnikova O, Gylfe A, Bailey L, et al. Osteoprotegerin promotes fibrous cap formation in atherosclerotic lesions of ApoE-deficient mice - brief report. Arterioscler Thromb Vasc Biol 2009;29:1478-80.
4. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
5. Dhore CR, Cleutjens JP, Lutgens E, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001;21:1998-2003. (Pubitemid 34219753)
6. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260-8. (Pubitemid 28213402)
7. Kudlacek S, Schneider B, Woloszczuk W, et al. Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone 2003;32:681-6. (Pubitemid 37303940)
8. Kazama JJ, Shigematsu T, Yano K, et al. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis 2002;39:525-32. (Pubitemid 34194628)
9. Secchiero P, Corallini F, Pandolfi A, et al. An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol 2006;169:2236-44. (Pubitemid 351181981)
10. Clancy P, Oliver L, Jayalath R, et al. Assessment of a serum assay for quantification of abdominal aortic calcification. Arterioscler Thromb Vasc Biol 2006;26:2574-6. (Pubitemid 44607454)
11. Jensen JK, Ueland T, Atar D, et al. Osteoprotegerin concentrations and prognosis in acute ischaemic stroke. J Intern Med 2010;267:410-17.
12. Jono S, Ikari Y, Shioi A, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002;106:1192-4. (Pubitemid 34988634)
13. Lieb W, Gona P, Larson MG, et al. Biomarkers of the osteoprotegerin pathway. Clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. Arterioscler Thromb Vasc Biol 2010;30:1849-54.
14. Omland T, Drazner MH, Ueland T, et al. Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. Hypertension 2007;49:1392-8. (Pubitemid 46809385)
15. Ueland T, Yndestad A, Oie E, et al. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 2005;111:2461-8. (Pubitemid 40696134)
16. Andersen GO, Knudsen EC, Aukrust P, et al. Elevated serum osteoprotegerin levels measured early after acute ST-elevation myocardial infarction predict final infarct size. Heart 2011;97:460-5.
17. Ueland T, Jemtland R, Godang K, et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 2004;44:1970-6. (Pubitemid 39473280)
18. Omland T, Ueland T, Jansson AM, et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol 2008;51:627-33. (Pubitemid 351193104)
19. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial. Am Heart J 2006;151:1186-9.
20. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA 2007;297:1775-83. (Pubitemid 46658646)
21. Roysland R, Masson S, Omland T, et al. Prognostic value of osteoprotegerin in chronic heart failure: the GISSI-HF trial. Am Heart J 2010;160:286-93.
22. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. Eur Heart J 2007;28:2525-38. (Pubitemid 47616190)
23. de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345:1014-21.
24. Morrow DA, de Lemos JA, Sabatine MS, et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 2003;41:1264-72. (Pubitemid 36438985)
25. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011;30:11-21.
26. Schnabel RB, Larson MG, Yamamoto JF, et al. Relation of multiple inflammatory biomarkers to incident atrial fibrillation. Am J Cardiol 2009;104:92-6.
27. Ueland T, Dahl CP, Kjekshus J, et al. Osteoprotegerin predicts progression of chronic heart failure: results from CORONA. Circ Heart Fail 2011;4:145-52.
28. Bennett BJ, Scatena M, Kirk EA, et al. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. Arterioscler Thromb Vasc Biol 2006;26:2117-24. (Pubitemid 44253797)
29. Cummings SR, San MJ, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-65.
30. Smith MR, Egerdie B, Hernandez TN, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009;361:745-55.